DG Capital Management (Massachusetts)’s Regeneron Pharmaceuticals REGN Stock Holding History

DG Capital Management (Massachusetts)’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$1.15M	Buy	+2,850	New	+$1.14M	1.13%	39
2016 Q1	–	Sell	-2,980	Closed	-$1.62M	–	73
2015 Q4	$1.62M	Sell	2,980 -1,955	-40%	-$1.06M	1.44%	30
2015 Q3	$2.29M	Buy	4,935 +280	+6%	+$150K	1.55%	30
2015 Q2	$2.38M	Sell	4,655 -1,025	-18%	-$500K	1.43%	35
2015 Q1	$2.56M	Buy	5,680 +2,270	+67%	+$962K	1.54%	28
2014 Q4	$1.4M	Sell	3,410 -550	-14%	-$216K	0.81%	55
2014 Q3	$1.43M	Sell	3,960 -2,758	-41%	-$924K	0.87%	49
2014 Q2	$1.9M	Sell	6,718 -5,030	-43%	-$1.49M	1.08%	49
2014 Q1	$3.53M	Sell	11,748 -2,510	-18%	-$773K	2.09%	17
2013 Q4	$3.92M	Buy	14,258 +975	+7%	+$280K	2.19%	21
2013 Q3	$4.16M	Buy	+13,283	New	+$3.49M	2.36%	7

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

DG Capital Management (Massachusetts)'s REGN Position: Q3 2016 in Review

DG Capital Management (Massachusetts) opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2016: 2,850 shares worth $1.15M. The stake represents 1.13% of the portfolio and ranks #39 among its holdings. This is a return to the name: DG Capital Management (Massachusetts) previously reported a position in REGN as recently as Q4 2015.

DG Capital Management (Massachusetts) first reported a position in REGN in Q3 2013 and has held it in 11 quarters since. The position peaked at $4.16M in Q3 2013. 553 funds tracked by Wall St. Rank hold REGN as of Q3 2016.

DG Capital Management (Massachusetts) held 2,850 shares of Regeneron Pharmaceuticals worth $1.15M as of Q3 2016.
Regeneron Pharmaceuticals was a new DG Capital Management (Massachusetts) position in Q3 2016.
Regeneron Pharmaceuticals made up 1.13% of DG Capital Management (Massachusetts)'s portfolio in Q3 2016, its #39 holding.
DG Capital Management (Massachusetts) first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 11 quarters since.
DG Capital Management (Massachusetts)'s Regeneron Pharmaceuticals position peaked at $4.16M in Q3 2013.
553 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2016.

Based on DG Capital Management (Massachusetts)'s 13F filing for Q3 2016, filed 21 Oct 2016.